Comparison of fluorescence polarization immunoassay with liquid chromatography for quantification of procainamide and N-acetylprocainamide in urine

Therapeutic Drug Monitoring

Volumn 18, Issue 6, 1996, Pages 693-697

  Tisdale, James E ^a,b   Padhi, I Desmond ^a,b   Ware, Joseph A ^a   Svensson, Craig K ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

Drugs assay; Immunoassay; N Acetylprocainamide; Procainamide; Urine

Indexed keywords

ACECAINIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRATE; PROCAINAMIDE; PROPRANOLOL;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MONITORING; DRUG URINE LEVEL; FLUORESCENCE POLARIZATION IMMUNOASSAY; HEART ARRHYTHMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL;

ACECAINIDE; ANTI-ARRHYTHMIA AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMANS; PROCAINAMIDE; REPRODUCIBILITY OF RESULTS;

EID: 0029834858     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199612000-00011     Document Type: Article

References (13)

1. Jolley ME. Fluorescence polarization immunoassay for the determination of therapeutic drug levels in human plasma. J Anal Toxicol 1981;5:236-40.
2. Al-Fares AM. Evaluation of the fluorescence polarization immunoassay for quantitation of digoxin in serum. Ther Drug Monit 1984;6:454-7.
3. Ristuccia PA, Ristuccia AM, Bidanset JH, Cunha BA. Comparison of bioassay, high-performance liquid chromatography, and fluorescence polarization immunoassay for quantitative determination of vancomycin in serum. Ther Drug Monit 1984;6:238-42.
4. Wilson JF, Williams J, Tsanaclis LM, Tedstone JE, Richens A. Evaluation of chromatographic and kit immunoassay techniques for the measurement of theophylline in serum: a study based on external quality assurement measurements. Ther Drug Monit 1988;10:438-45.
5. Bryson SM, Leson CL, Irwin DB, Trope AE, Hosking MCK. Therapeutic monitoring and pharmacokinetic evaluation of procainamide in neonates. DICP Ann Pharmacother 1991;25:68-71.
6. Tisdale JE, Rudis MI, Padhi ID, et al. Disposition of procainamide in patients with chronic congestive heart failure receiving medical therapy. J Clin Pharmacol 1996;36:35-41.
7. Liu L-L, Knowlton PW, Svensson CK. Effect of amiodarone on the disposition of procainamide in the rat. J Pharm Sci 1988;77:662-5.
8. Tisdale JE, Rudis MI, Padhi ID, et al. Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in human subjects. J Clin Pharmacol 1995;35:902-10.
9. Assay manual for TDX/TDxFLx Systems, Abbott Diagnostics, Division of Abbott Laboratories, Abbott Park, IL, 1993.
10. Lima JJ, Jusko WJ. Determination of procainamide acetylator status. Clin Pharmacol Ther 1978;23:25-9.
11. du Souich P, Erill S. Metabolism of procainamide and p-aminobenzoic acid in patients with chronic liver disease. Clin Pharmacol Ther 1978;22:588-95.
12. Wood WG. Matrix effects in immunoassays. Scand J Clin Lab Invest 1991;51:105-12.
13. MacKichan JJ, Coyle JD, Shields BJ, Boudoulas H, Lima JJ. Fluoroimmunoassays for procainamide and N-acetylprocainamide compared with a liquid-chromatographic method. Clin Chem 1984;30:768-73.